Barclays
LAB icon

Barclays’s Standard BioTools LAB Stock Holding History

Barclays’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-70,000
Closed -$524K – 7137
2018
Q3 		$524K Buy
+70,000
New +$498K ﹤0.01% 4234

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Barclays's LAB Position: Q1 2026 in Review

Barclays reduced its Standard BioTools (LAB) stake by 15% in Q1 2026, selling an estimated $560K and leaving 2,617,969 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

Barclays first reported a position in LAB in Q2 2013 and has held it in 47 quarters since. The position peaked at $10.7M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Barclays held 2,617,969 shares of Standard BioTools worth $2.41M as of Q1 2026.
  • Barclays sold 462,610 Standard BioTools shares in Q1 2026, an estimated $560K.
  • Standard BioTools made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2234 holding.
  • Barclays first reported a position in Standard BioTools in Q2 2013 and has held it in 47 quarters since.
  • Barclays's Standard BioTools position peaked at $10.7M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.